CRITICAL THERAPEUTICS

๐Ÿ‡บ๐Ÿ‡ธUnited States
Ownership
-
Employees
-
Market Cap
-
Website
Clinical Trials
Related News

Assessment of PFT, Safety, and PK of Zileuton Injection in Asthma Patients

Phase 2
Completed
Conditions
Asthma
Interventions
Drug: zileuton
Drug: placebo
First Posted Date
2007-09-26
Last Posted Date
2008-03-21
Lead Sponsor
Critical Therapeutics
Target Recruit Count
36
Registration Number
NCT00534625

Zileuton CR vs Placebo in Poorly Controlled Asthma Patients on Moderate Dose ICS

Phase 4
Terminated
Conditions
Asthma
Interventions
Drug: Placebo
Drug: Zileuton CR
First Posted Date
2007-06-14
Last Posted Date
2008-04-03
Lead Sponsor
Critical Therapeutics
Target Recruit Count
400
Registration Number
NCT00486343
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Critical Therapeutics, Lexington, Massachusetts, United States

Safety Study of Zileuton Injection in Patients With Asthma

Phase 1
Completed
Conditions
Asthma
First Posted Date
2006-03-06
Last Posted Date
2007-09-26
Lead Sponsor
Critical Therapeutics
Target Recruit Count
60
Registration Number
NCT00299065
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Allergy and Asthma Medical Group and Research Center, San Diego, California, United States

๐Ÿ‡บ๐Ÿ‡ธ

Colorado Allergy and Asthma Centers, PC, Englewood, Colorado, United States

๐Ÿ‡บ๐Ÿ‡ธ

Northeast Medical Research Associates, North Dartmouth, Massachusetts, United States

and more 7 locations

CTI-01 (Ethyl Pyruvate) Safety and Complication Prevention in Cardiac Surgery Patients on Cardiopulmonary Bypass (CPB)

Phase 2
Terminated
Conditions
Heart Valve Diseases
Coronary Disease
First Posted Date
2005-04-07
Last Posted Date
2006-03-17
Lead Sponsor
Critical Therapeutics
Target Recruit Count
150
Registration Number
NCT00107666
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Kaiser Permanente, San Francisco, California, United States

๐Ÿ‡บ๐Ÿ‡ธ

NYU Medical Center, New York, New York, United States

๐Ÿ‡บ๐Ÿ‡ธ

Saddleback Memorial Medical Center, Laguna Hills, California, United States

and more 14 locations

Study of Oral Zileuton in the Treatment of Moderate to Severe Facial Acne Vulgaris

Phase 2
Conditions
Acne Vulgaris
First Posted Date
2004-12-08
Last Posted Date
2007-02-07
Lead Sponsor
Critical Therapeutics
Target Recruit Count
90
Registration Number
NCT00098358
Locations
๐Ÿ‡บ๐Ÿ‡ธ

Rivergate Dermatology, Goodlettsville, Tennessee, United States

๐Ÿ‡บ๐Ÿ‡ธ

SUNY Downstate Medical Center, Brooklyn, New York, United States

๐Ÿ‡บ๐Ÿ‡ธ

Dermatology Associates of Rochester, Rochester, New York, United States

and more 9 locations
ยฉ Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy